Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-03
DOI
10.1038/s41598-017-15172-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interplay between Fanconi anemia and homologous recombination pathways in genome integrity
- (2016) Johanna Michl et al. EMBO JOURNAL
- The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells
- (2016) Ping Chen et al. CELLULAR ONCOLOGY
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models
- (2015) Darlene Barnard et al. INVESTIGATIONAL NEW DRUGS
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine
- (2013) Kirtee Raparia et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
- (2013) Ruth Thompson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
- (2013) C. G. Engelke et al. CLINICAL CANCER RESEARCH
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- (2012) Maurice Pérol et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
- (2012) Ruth Thompson et al. PLoS One
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Claspin and Chk1 regulate replication fork stability by different mechanisms
- (2011) Jennifer Scorah et al. CELL CYCLE
- Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase
- (2011) Samuel McNeely et al. CELL CYCLE
- Pathology of Lung Cancer
- (2011) William D. Travis CLINICS IN CHEST MEDICINE
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Maintaining genome stability at the replication fork
- (2010) Dana Branzei et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
- (2010) Cynthia X. Ma et al. TRENDS IN MOLECULAR MEDICINE
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid -amide]
- (2009) A. G. Jobson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
- (2009) L. A. Parsels et al. MOLECULAR CANCER THERAPEUTICS
- Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy
- (2008) P.H. Clingen et al. BIOCHEMICAL PHARMACOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
- (2008) A. Blasina et al. MOLECULAR CANCER THERAPEUTICS
- The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
- (2008) E M Bahassi et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started